Related Experiment Video
Updated: Aug 21, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
Published on: January 31, 2020
Is JAK3 a new drug target for immunomodulation-based therapies?
Anastassios C Papageorgiou1, Linnea E K Wikman
1Turku Centre for Biotechnology, University of Turku and Abo Akademi University, Turku 20521, Finland. apapageo@btk.utu.fi
Abstract:
JAK3, a member of the Janus kinase family, has a crucial role in T-cell development and the homeostasis of the immune system because of its association with the common gamma chain (gammac) of cytokine receptors. Disruption of either JAK3 or gammac expression results in severe combined immunodeficiency disease. Thus, JAK3 has attracted significant attention in recent years as a target for therapeutic intervention in several immune-related diseases. Inhibitors of JAK3 have been developed that might act as either immunosuppressive agents in human organ transplantation or as immunomodulators in autoimmune disorders. We propose that targeting JAK3 offers alternative avenues for the development of new immunomodulatory strategies of therapeutic value. Furthermore, we believe that in addition to the tyrosine kinase domain of JAK3, where inhibitor design efforts are currently focused, non-catalytic regions of JAK3 might represent candidate targets for future drugs.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Tumor Immunotherapy
The JAK-STAT Signaling Pathway
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inhibitors of Viral Protein Synthesis